Activity of closantel in the prevention of Gasterophilus and Strongylus vulgaris larval infections in equine foals and yearlings.
Two controlled tests were conducted in equine foals and yearlings to determine the optimal oral dosage and the duration of activity of closantel for the prevention of Gasterophilus spp larval infections. Additional data were collected on the activity of closantel against Strongylus vulgaris larval infections. In experiment 1, 12 foals and 12 yearlings were equally allocated to 4 experimental groups, and were given oral treatments with closantel at dosages of 0 (nontreated controls), 2, 5, or 8 mg/kg of body weight every 2 months during bot season. The foals and yearlings were allowed to graze on open pasture throughout the experiment to provide a natural source for bot and helminth infections. All animals were euthanatized and necropsied 6 weeks after the final treatment. Closantel was highly effective (98.6% to 100%) at all doses in preventing Gasterophilus spp larval infections in the foals, but only the 8 mg/kg dose had significant (P less than 0.05) activity (99.7%) in the yearlings. This dose also significantly reduced the numbers of 4th-stage and immature adult S vulgaris (86.0%) in the mesenteric arteries as compared with nontreated controls. In experiment 2, 9 foals and 9 yearlings received a single oral treatment of 8 mg of closantel/kg of body weight; 3 foals and 3 yearlings were kept as nontreated controls. Groups of 6 treated (3 foals, 3 yearlings) and 2 control (1 foal, 1 yearling) animals were euthanatized and necropsied 1, 2, and 3 months after treatment. Closantel remained effective for 2 months in preventing infections of G intestinalis larvae in these foals and yearlings. Clinical signs of toxicosis were not observed in the treated animals of either study.
D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D004175:Diptera; D004386:Duodenum / Q000469:parasitology; D005260:Female; D006734:Horse Diseases / Q000469:parasitology / Q000517:prevention & control*; D006736:Horses; D007814:Larva; D008297:Male; D008638:Mesenteric Arteries / Q000469:parasitology; D009198:Myiasis / Q000469:parasitology / Q000517:prevention & control / Q000662:veterinary*; D012457:Salicylamides / Q000627:therapeutic use*; D012458:Salicylanilides / Q000627:therapeutic use*; D013270:Stomach / Q000469:parasitology; D013319:Strongyle Infections, Equine / Q000469:parasitology / Q000517:prevention & control*; D013320:Strongyloidea
D000871:Anthelmintics; D012457:Salicylamides; D012458:Salicylanilides; C023342:closantel